Skip to main content

Development of Stem Cell Based Therapy for Thymic Regeneration

Objetivo

Reconstitution of immune system function in immunocompromised patients depends on the presence of a functional thymus, and specifically, on the diverse array of epithelial cells within the thymic stroma. The thymus is the first organ to degenerate in normal healthy individuals, and is also sensitive to cytotoxic interventions. Therefore lack of thymic function presents a serious problem for many patients. Transplantation of neonatal human thymus can lead to successful immune system reconstitution, but limited tissue supply prevents its widespread use. Thymic epithelial stem cells (TESC), which can generate all of the epithelial subpopulations of the adult thymus, present an alternative source of transplantable cells. However, protocols for growing or generating TESC in the laboratory have not yet been developed. This proposal aims to develop robust and scalable protocols for the long-term in vitro culture of functionally validated human TESC, including standardized quality controls, and to establish optimized means of delivering these cells to immunocompromised recipients such that thymus function is fully restored. It also aims to develop optimized procedures for cryopreservation of human thymic stromal cells. These objectives relate directly to the topic identified in call HEALTH.2013.1.4-1 Controlling differentiation and proliferation in human stem cells intended for therapeutic use. THYMISTEM brings together a strong, pan-European team comprising thymus and stem cell biologists, immunologists working in humanized mouse models, haematologists expert in immune reconstitution, tissue engineers, and experts in cryopreservation and cell banking, to deliver these goals. Overall, this work will build the preclinical foundations required for development of a novel stem-cell based therapy: transplantation of thymic epithelial stem cell-based organoids for regenerative recovery of thymic - and thus immune system - function in patients.

Convocatoria de propuestas

FP7-HEALTH-2013-INNOVATION-1
Consulte otros proyectos de esta convocatoria

Coordinador

THE UNIVERSITY OF EDINBURGH
Dirección
Old College, South Bridge
EH8 9YL Edinburgh
United Kingdom

Ver en el mapa

Tipo de actividad
Higher or Secondary Education Establishments
Contacto administrativo
Alan Kennedy (Mr.)
Aportación de la UE
€ 2 135 920,50

Participantes (6)

AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS
España
Aportación de la UE
€ 793 180,35
Dirección
Calle Serrano 117
28006 Madrid

Ver en el mapa

Tipo de actividad
Research Organisations
Contacto administrativo
María ángeles López Váquez (Ms.)
RUDER BOSKOVIC INSTITUTE
Croacia
Aportación de la UE
€ 500 521,60
Dirección
Bijenicka Cesta 54
10000 Zagreb

Ver en el mapa

Tipo de actividad
Research Organisations
Contacto administrativo
Marijana Klasnic Kozar (Ms.)
OPEN INTERNATIONAL UNIVERSITY OF HUMAN DEVELOPMENT UKRAINE
Ucrania
Aportación de la UE
€ 720 000,20
Dirección
Khoryva 1-g
04071 Kyiv

Ver en el mapa

Tipo de actividad
Higher or Secondary Education Establishments
Contacto administrativo
Valentin Shichkin (Prof.)
YEDITEPE UNIVERSITY VAKIF

La participación finalizó

Turquía
Aportación de la UE
€ 122 832,10
Dirección
Kayisdagi Street Agustos Campus 26
81120 Istanbul

Ver en el mapa

Tipo de actividad
Higher or Secondary Education Establishments
Contacto administrativo
Ozge Kaya (Ms.)
NANOPHARMA AS
Chequia
Aportación de la UE
€ 899 472,92
Dirección
Nova 306
530 09 Pardubice

Ver en el mapa

Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contacto administrativo
Katerina Lajblova (Ms.)
Sloan-Kettering Institute for Cancer Research CORPORATION
Estados Unidos
Aportación de la UE
€ 824 527,80
Dirección
York Avenue 1275
10065 New York

Ver en el mapa

Tipo de actividad
Research Organisations
Contacto administrativo
Mark Svenningson (Mr.)